Skip to content
Screener

Other Income (Expense) at other companies

Veradermics logo
VeradermicsMANE
$2.63M+411%
GPA
General Purpose Acquisition Corp.GPAC
-$1.25M-164%
Dycom Industries logo
Dycom IndustriesDY
-$1.51M-121%
Target logo
TargetTGT
$15M-42.3%
Edison International logo
Edison InternationalEIX
$121M+13.1%
Analog Devices logo
Analog DevicesADI
-$54.85M-5.5%

Where this comes from

Reported directly by First Tracks Biotherapeutics Inc in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: First Tracks Biotherapeutics Inc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:32 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-224190
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Loss from operations(52,811)(51,280)
Other income (expense), net:
Interest income2,3284,091
Other expense, net(1)(7)
Total other income, net2,3274,084
Net loss(50,484)(47,196)
Unrealized loss on available-for-sale securities(122)(144)
Comprehensive loss$(50,606)$(47,340)

Item 1. Combined Financial Statements.

FAQ

What is First Tracks Biotherapeutics Inc's other income (expense)?
First Tracks Biotherapeutics Inc (TRAX) reported other income (expense) of $2.33M in Q1 2026.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about First Tracks Biotherapeutics Inc's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude